Introduction
Actinomyces israelii is a Gram-positive, non-spore-forming, filamentous, facultatively anaerobic bacterium that belongs to the genus Actinomyces, family Actinomycetaceae. First identified in the late 19th century by James Israel, this bacterium is now recognized as the primary causative agent of actinomycosis, a chronic granulomatous disease marked by abscess formation, draining sinuses, and the presence of characteristic sulfur granules.
While A. israelii is typically a commensal organism in the oropharynx, gastrointestinal tract, and female genital tract, it becomes pathogenic when mucosal barriers are breached. This review explores the morphology, virulence, pathogenesis, diagnostic approaches, treatment strategies, and its clinical implications in both localized and systemic infections.
Morphology and Growth Characteristics
Actinomyces israelii exhibits the following features:
- Gram-positive, non–acid-fast rods with filamentous branching structures
- Non-motile, non-spore-forming
- Colonies on solid media appear as molar tooth-shaped, rough, and adherent
- Facultative or strict anaerobe (depending on strain)
- Catalase-negative and indole-negative
It thrives in low-oxygen environments and is part of the normal flora of the mouth, tonsillar crypts, and dental plaque. Its ability to form dense biofilms and adhere to mucosal surfaces enables long-term colonization.
Habitat and Colonization
- israelii colonizes:
- Oral cavity: gingival crevices, tonsils, dental plaque
- Gastrointestinal tract: especially appendix and cecum
- Female genital tract: particularly in women using intrauterine devices (IUDs)
It is typically harmless in these locations unless trauma, surgery, or immunosuppression provides a route of entry to deeper tissues.
Pathogenic Role
The pathogenesis of Actinomyces israelii is unique in that it causes chronic, slowly progressive infections that mimic malignancies or other deep-seated diseases.
1. Cervicofacial Actinomycosis
This is the most common form, accounting for about 50–70% of cases. It typically results from:
- Dental caries
- Oral trauma
- Poor oral hygiene
- Post-dental surgery
Clinical signs include:
- Hard, painless swelling on the jaw or neck
- Formation of draining sinuses
- Pus containing sulfur granules (yellowish aggregates of bacteria)
2. Thoracic Actinomycosis
Occurs from aspiration of oral secretions or spread from the cervical region. It may present as:
- Lung consolidation
- Chest wall masses
- Pleural effusions
- Fistula formation
Radiologically, it mimics tuberculosis or cancer.
3. Abdominal and Pelvic Actinomycosis
- May follow gastrointestinal surgeries, IUD use, or appendicitis
- Presents with abdominal mass, weight loss, or fever
- IUD-associated actinomycosis can extend to involve the uterus, ovaries, and even bowel
4. Central Nervous System (CNS) Actinomycosis
- Very rare but serious
- Brain abscesses or meningitis-like symptoms may occur
Virulence Factors
- israelii possesses several mechanisms that contribute to its pathogenicity:
- Biofilm formation: Enhances resistance to antibiotics and immune clearance
- Surface adhesins: Allow adherence to host epithelium
- Chronic granulomatous inflammation: Induces tissue fibrosis
- Sulfur granules: Help in immune evasion and serve as a diagnostic hallmark
It is a low-virulence organism, and its ability to cause disease often relies on the host’s impaired defense mechanisms.
Diagnosis
Diagnosing actinomycosis is often delayed because the infection mimics other conditions like malignancy or tuberculosis.
Laboratory Diagnosis
- Microscopy: Gram stain shows filamentous Gram-positive rods in sulfur granules
- Culture:
- Anaerobic culture is required
- Growth takes 5–20 days
- Histology: Shows suppurative granulomas and sulfur granules
- Imaging: CT and MRI can reveal abscesses and sinus tracts but are non-specific
Molecular Diagnosis
- PCR and 16S rRNA gene sequencing help confirm the presence of A. israelii
- Useful in culture-negative cases
Differential Diagnosis
- Tuberculosis
- Fungal infections (e.g., nocardiosis, aspergillosis)
- Squamous cell carcinoma
- Sarcoidosis
Treatment
The cornerstone of treatment is prolonged antibiotic therapy, often combined with surgical drainage.
Antibiotic Therapy
- Penicillin G: First-line agent
- Intravenous for 2–6 weeks followed by oral for 6–12 months
- Alternatives: Amoxicillin, doxycycline, clindamycin
- Metronidazole is ineffective against Actinomyces
Surgical Intervention
- May be required for draining abscesses, removing necrotic tissue, or managing fistulas
- In IUD-associated cases, removal of the device is essential
Prognosis
The prognosis of actinomycosis caused by A. israelii is generally good with early diagnosis and adequate treatment. Delayed treatment can lead to extensive fibrosis, abscess formation, and significant morbidity.
Prevention
- Good oral hygiene
- Regular dental checkups
- Avoid prolonged use of intrauterine devices
- Proper wound care after surgery or trauma
Conclusion
Actinomyces israelii is a significant, albeit often overlooked, pathogen responsible for chronic and invasive infections, especially in the cervicofacial region. Its low virulence, delayed culture growth, and mimicking of other diseases often complicate diagnosis. Timely recognition and prolonged antibiotic therapy remain the mainstay of treatment. Continued awareness among clinicians, especially dentists and surgeons, is vital to reduce diagnostic delays and ensure effective management.
References
- Könönen E, Wade WG. Actinomyces and related organisms in human infections. Clin Microbiol Rev. 2015;28(2):419–442. doi:10.1128/CMR.00100-14
- Russo TA. Agents of actinomycosis. In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 9th ed. Elsevier; 2020.
- Pulverer G, et al. Human infections due to Actinomyces israelii: A review of 117 cases. Infection. 2003;31(1):39–45.
- Acevedo F, et al. Actinomycosis: A great pretender. Case report and review of literature. Int J Infect Dis. 2008;12(4):358–362.
- Smego RA, Foglia G. Actinomycosis. Clin Infect Dis. 1998;26(6):1255–1263.
- Wong VK, Turmezei TD, Weston VC. Actinomycosis. BMJ. 2011;343:d6099. doi:10.1136/bmj.d6099
- Valour F, et al. Actinomycosis: Etiology, clinical features, diagnosis, treatment, and management. Infect Drug Resist. 2014;7:183–197.
- Hall V. Actinomyces–gathering evidence of human infections. Anaerobe. 2008;14(1):1–7.
